Skip to content

Study · Non-randomized trial · 2018

6 results

More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.

Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR

Diabetes, obesity & metabolism13 Jun 2018Cited by 12 (Europe PMC)

PMID29785837 (opens in a new tab)PMCIDPMC6099242 (opens in a new tab)DOI10.1111/dom.13368 (opens in a new tab)PepBankPUB-29785837
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with uncontrolled type 2 diabetes on oral drugs, adding lixisenatide increased target HbA1c attainment versus insulin glargine alone.

    In plain wordsAdding lixisenatide increased target blood sugar attainment compared with insulin glargine alone in patients previously receiving oral drugs.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target attainment at 12 weeks, LixiLan-O
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    HbA1c target attainment
    60%
    iGlarLixi, LixiLan-O
    HbA1c target attainment
    45%
    iGlar, LixiLan-O

    Source sentences

    Summary
    In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar.
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with uncontrolled type 2 diabetes on basal insulin, adding lixisenatide increased target HbA1c attainment versus insulin glargine alone.

    In plain wordsAdding lixisenatide increased target blood sugar attainment compared with insulin glargine alone in patients previously receiving basal insulin.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target attainment at 12 weeks, LixiLan-L
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    HbA1c target attainment
    46%
    iGlarLixi, LixiLan-L
    HbA1c target attainment
    24%
    iGlar, LixiLan-L

    Source sentences

    Summary
    In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar.
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…
  3. 03HumanNon-randomized trialEfficacy outcome

    In LixiLan-O patients with type 2 diabetes, median time to target HbA1c was shorter with added lixisenatide than insulin glargine alone.

    In plain wordsAdding lixisenatide shortened time to target blood sugar compared with insulin glargine alone in LixiLan-O.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTime to target HbA1c, LixiLan-O
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median time
    85 days
    iGlarLixi
    Median time
    166 days
    iGlar
    P value
    < 0.0001
    between treatments

    Source sentences

    Summary
    In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P < .0001).
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…
  4. 04HumanNon-randomized trialEfficacy outcome

    In LixiLan-L patients, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with insulin glargine alone (P < .0001).

    In plain wordsAdding lixisenatide shortened time to target blood sugar compared with insulin glargine alone in LixiLan-L.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTime to target HbA1c, LixiLan-L
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median time to target HbA1c
    153 days
    iGlarLixi, LixiLan-L
    Patients who never reached target HbA1c
    50%
    iGlar, LixiLan-L
    P value
    < 0.0001
    between treatments

    Source sentences

    Summary
    In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P < .0001).
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, time to target fasting glucose was similar with added lixisenatide and insulin glargine alone.

    In plain wordsTime to target fasting blood sugar was similar with added lixisenatide and insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTime to target fasting plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Time-to-target FPG and hypoglycaemia outcomes were similar between treatments.
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…
  6. 06HumanNon-randomized trialSafety outcome

    In patients with type 2 diabetes, hypoglycaemia outcomes were similar with added lixisenatide and insulin glargine alone.

    In plain wordsLow blood sugar outcomes were similar with added lixisenatide and insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedHypoglycaemia outcomes
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Time-to-target FPG and hypoglycaemia outcomes were similar between treatments.
    1 context sentence
    Summary · context
    The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.